Question 1

Which countries lead Biosimilars and Bioanalytical Methods research?

Accepted Answer

By volume, the United States and China publish the most (1.3k and 389 works in 2022-now).

Question 2

Which institutions lead Biosimilars and Bioanalytical Methods research?

Accepted Answer

By volume in 2022-now, Harvard University publishes the most Biosimilars and Bioanalytical Methods research, followed by Pfizer (United States) and Johnson & Johnson (United States).

Question 3

Who are the leading researchers in Biosimilars and Bioanalytical Methods?

Accepted Answer

The most-cited researchers publishing on Biosimilars and Bioanalytical Methods include Gad A. Getz, John J.V. McMurray and Cyrus Cooper.

Question 4

Where is Biosimilars and Bioanalytical Methods research done?

Accepted Answer

The largest centres of Biosimilars and Bioanalytical Methods research in 2022-now are London (United Kingdom), New York (United States), Beijing (China) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Silver Spring.

Question 5

Where is the best place to study Biosimilars and Bioanalytical Methods?

Accepted Answer

Among universities, judged by research, Harvard University, KU Leuven and University of Oslo score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Biosimilars and Bioanalytical Methods research growing?

Accepted Answer

Output in 2022-2025 was 15% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Biosimilars and Bioanalytical Methods.

Question 7

What are the most cited papers in Biosimilars and Bioanalytical Methods?

Accepted Answer

The most cited paper in Biosimilars and Bioanalytical Methods is "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update" (Josef S Smolen et al., 2017), with 5,808 citations. Next come "The price of innovation: new estimates of drug development costs" (4,325) and "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" (4,190).